← Back to Search

Janus Kinase (JAK) Inhibitor

Upadacitinib for Atopic Dermatitis

Phase 3
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to 30 days following last dose of study drug (week 52)
Awards & highlights

Study Summary

This trial is for people who have finished treatment with Dupilumab or Upadacitinib and want to continue with Upadacitinib for 52 weeks. The goal is to see if it is safe and effective.

Eligible Conditions
  • Atopic Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to 30 days following last dose of study drug (week 52)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to 30 days following last dose of study drug (week 52) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Adverse Events

Side effects data

From 2023 Phase 3 trial • 613 Patients • NCT03086343
6%
URINARY TRACT INFECTION
5%
UPPER RESPIRATORY TRACT INFECTION
5%
NASOPHARYNGITIS
3%
HYPERTENSION
100%
80%
60%
40%
20%
0%
Study treatment Arm
Abatacept
Upadacitinib 15 mg

Trial Design

1Treatment groups
Experimental Treatment
Group I: UpadacitinibExperimental Treatment1 Intervention
Participants will be administered with upadacitinib once daily (QD)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Upadacitinib
FDA approved

Find a Location

Who is running the clinical trial?

AbbVieLead Sponsor
954 Previous Clinical Trials
500,620 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
394 Previous Clinical Trials
145,454 Total Patients Enrolled

Media Library

Upadacitinib (Janus Kinase (JAK) Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04195698 — Phase 3
Atopic Dermatitis Research Study Groups: Upadacitinib
Atopic Dermatitis Clinical Trial 2023: Upadacitinib Highlights & Side Effects. Trial Name: NCT04195698 — Phase 3
Upadacitinib (Janus Kinase (JAK) Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04195698 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this the first time that Upadacitinib has been trialed?

"Upadacitinib was first evaluated in 2015 through Arthritis Clinical Research Tr /ID# 144874. 21 more studies have completed since then. There are 21 more active trials happening now, a significant proportion of which are based in Santa Monica, California."

Answered by AI

Have there been previous studies like this one?

"To date, there have been 21 clinical trials completed for Upadacitinib across 54 countries and 953 cities. The first trial was conducted in 2015 by AbbVie and completed Phase 3 approval in that same year. A total of 1629 patients were involved."

Answered by AI

For this particular test, are only adults allowed to participate?

"The age requirements for this clinical trial are between 18-75 years old. If you don't meet this age criteria, there are still options available as there are 112 trials for people under 18 and 201 for patients over 65."

Answered by AI

What are some potential dangers of Upadacitinib?

"Upadacitinib has received a Phase 3 safety rating from our team at Power, meaning that there is both efficacy and safety data supporting its use."

Answered by AI

For what medical purpose is Upadacitinib most often prescribed?

"Upadacitinib is given to patients who are candidates for systemic therapy in order to treat their rheumatoid arthritis, methotrexate, or other condition that did not respond well to conventional treatments."

Answered by AI

How many places are testing this out right now?

"Currently, this trial is recruiting patients from 43 sites. The locations are located in Santa Monica, Tulsa, Tampa and other locations. To minimize travel demands, it is important to select the clinic closest to you if you participate."

Answered by AI

Are there any enrollments still available for this research project?

"This study is no longer actively recruiting participants. It was originally posted on 1/15/2020 and was last updated on 7/27/2022. If you are looking for other studies, there are currently 255 trials actively enrolling participants with dermatitis and 21 studies for Upadacitinib actively enrolling patients."

Answered by AI

Who else is applying?

What state do they live in?
California
Indiana
New York
Other
How old are they?
18 - 65
What site did they apply to?
Ucsd /Id# 218629
Dawes Fretzin, LLC /ID# 218478
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
Recent research and studies
clinicaltrials.govStudy
Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
2020. "Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04195698.
~92 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top